Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ondansetron
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Athena’s First Market Authorization in Brazil with Ondansetron ODT
Details : Ondansetron Oro-Dispersible Tablet is pleasant and convenient as a tablet that melts in mouth and can be administered anytime anywhere with or without water,is used alone or with other medications to prevent nausea and vomiting caused by cancer drug trea...
Brand Name : Ondansetron-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 15, 2022
Lead Product(s) : Ondansetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : NFL-301
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : NFL Biosciences
Deal Size : Undisclosed
Deal Type : Agreement
NFL BIOSCIENCES: Co-development Agreement For A Drug Candidate to Reduce Alcohol Consumption
Details : Under the terms of the agreement, ATHENA Pharmaceutiques will manage the development and manufacturing of NFL-301, a natural drug candidate from NFL Biosciences aimed at reducing alcohol consumption, while NFL Biosciences will draw up and lead the clinic...
Brand Name : NFL-301
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 02, 2022
Lead Product(s) : NFL-301
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : NFL Biosciences
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Bisoprolol Fumarate,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Deal Size : Undisclosed
Deal Type : Acquisition
Athena Pharmaceutiques Acquires Bisoprolol + Aspirin Capsules Dossier and Patent
Details : ATHENA Pharmaceutiques has acquire the Bisoprolol + Aspirin Capsules dossier as well as the patent for this product. It is a fixed dose combination of two reference agents improving compliance and adherence to treatment in the secondary prevention of car...
Brand Name : Bisoprolol/Aspirin-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 15, 2021
Lead Product(s) : Bisoprolol Fumarate,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ATHENA’s First Launch in Russia with Levocetirizine ODT
Details : Levocetirizine ODT is second-generation piperazine derivative with potent H1-selective antihistaminic activity,n Improved oral bioavailability and onset of action vs. conventional oral slide form by avoiding hepatic first-pass effect.
Brand Name : Levocetirizine-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 12, 2020
Lead Product(s) : Levocetirizine Dihydrochloride
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?